WO2004062609A3 - Derives de pyrimidine utilises comme antagonistes des recepteurs de l'il-8 - Google Patents

Derives de pyrimidine utilises comme antagonistes des recepteurs de l'il-8 Download PDF

Info

Publication number
WO2004062609A3
WO2004062609A3 PCT/US2004/000584 US2004000584W WO2004062609A3 WO 2004062609 A3 WO2004062609 A3 WO 2004062609A3 US 2004000584 W US2004000584 W US 2004000584W WO 2004062609 A3 WO2004062609 A3 WO 2004062609A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
receptor antagonists
pyrimidine derivatives
compounds
formula
Prior art date
Application number
PCT/US2004/000584
Other languages
English (en)
Other versions
WO2004062609A2 (fr
Inventor
Shawn David Erickson
John J Baldwin
Ronald E Dolle Iii
James Inglese
Michael H J Ohlmeyer
Koc-Kan Ho
Adolph C Bohnstedt
Steven G Kultgen
Maria L Webb
Douglas S Auld
Andrew Laird Roughton
Paolo Giovanni Martino C Conti
Dirk Leysen
Der Louw Jaap Van
Original Assignee
Pharmacopeia Inc
Shawn David Erickson
John J Baldwin
Ronald E Dolle Iii
James Inglese
Michael H J Ohlmeyer
Koc-Kan Ho
Adolph C Bohnstedt
Steven G Kultgen
Maria L Webb
Douglas S Auld
Andrew Laird Roughton
Paolo Giovanni Martino C Conti
Dirk Leysen
Der Louw Jaap Van
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia Inc, Shawn David Erickson, John J Baldwin, Ronald E Dolle Iii, James Inglese, Michael H J Ohlmeyer, Koc-Kan Ho, Adolph C Bohnstedt, Steven G Kultgen, Maria L Webb, Douglas S Auld, Andrew Laird Roughton, Paolo Giovanni Martino C Conti, Dirk Leysen, Der Louw Jaap Van, Akzo Nobel Nv filed Critical Pharmacopeia Inc
Publication of WO2004062609A2 publication Critical patent/WO2004062609A2/fr
Publication of WO2004062609A3 publication Critical patent/WO2004062609A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés contenant un noyau pyrimidine ainsi que leur utilisation pour traiter des maladies et des états pathologiques associés à une activité inappropriée des récepteurs de l'interleukine 8. Ces composés sont représentés par la formule (I). Dans lesdits composés, Q est de préférence hétérocyclyle non substitué et substitué, U est normalement hydrogène ou fluor, et V est de préférence hydrogène, halogène, alkyle, -O-alkyle ou S-alkyle. La formule (X) constitue un exemple représentatif.
PCT/US2004/000584 2003-01-10 2004-01-09 Derives de pyrimidine utilises comme antagonistes des recepteurs de l'il-8 WO2004062609A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/340,398 2003-01-10
US10/340,398 US7037916B2 (en) 1999-07-15 2003-01-10 Pyrimidine derivatives as IL-8 receptor antagonists

Publications (2)

Publication Number Publication Date
WO2004062609A2 WO2004062609A2 (fr) 2004-07-29
WO2004062609A3 true WO2004062609A3 (fr) 2004-11-25

Family

ID=32711323

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/000584 WO2004062609A2 (fr) 2003-01-10 2004-01-09 Derives de pyrimidine utilises comme antagonistes des recepteurs de l'il-8

Country Status (2)

Country Link
US (1) US7037916B2 (fr)
WO (1) WO2004062609A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008228768A1 (en) * 2007-03-22 2008-09-25 Vertex Pharmaceuticals Incorporated N-heterocyclic compounds useful as inhibitors of Janus Kinases
DE102010000662A1 (de) 2009-03-18 2010-10-21 Bayer Cropscience Ag Aminopropylthiazol-Derivate als Fungizide
BR112014016147B8 (pt) * 2011-12-30 2022-10-11 Dow Agrosciences Llc Pirimidinas-2,6-dialo-5-alcóxi-4-substituídas, pirimidina-carbaldeídos, e seus métods de formação e uso
IN2014DN07636A (fr) 2012-03-16 2015-05-15 Vitae Pharmaceuticals Inc
RS55532B1 (sr) 2012-03-16 2017-05-31 Vitae Pharmaceuticals Inc Modulatori jetrenog x receptora
CN103374005B (zh) * 2012-04-11 2016-12-14 南京信诺泰医药有限公司 取代呋喃并哌啶衍生物的合成新方法
EP2988742A4 (fr) * 2013-04-22 2016-10-19 Abbvie Inc Thiazoles et utilisations de ceux-ci
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
CN109890364B (zh) * 2016-10-03 2023-10-17 儿童医疗中心公司 糖尿病肾病的预防和治疗

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0826673A1 (fr) * 1995-04-13 1998-03-04 Dainippon Pharmaceutical Co., Ltd. Derives de l'acetamide, procede de fabrication et composition medicamenteuse a base de ces derives
JPH10130150A (ja) * 1996-09-05 1998-05-19 Dainippon Pharmaceut Co Ltd 酢酸アミド誘導体からなる医薬
WO1998037079A1 (fr) * 1997-02-19 1998-08-27 Berlex Laboratories, Inc. Derives n-heterocycliques utiles en tant qu'inhibiteurs de la no synthetase
WO2001005783A1 (fr) * 1999-07-15 2001-01-25 Pharmacopeia, Inc. Antagonistes du recepteur b1 de la bradykinine
EP1110951A1 (fr) * 1998-08-27 2001-06-27 Sumitomo Pharmaceuticals Company, Limited Derives de pyrimidine
WO2003002542A1 (fr) * 2000-12-22 2003-01-09 Bristol-Myers Squibb Company Inhibiteurs n-heterocycliques de l'expression de tnf-alpha
WO2003077656A1 (fr) * 2002-03-15 2003-09-25 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines et leur utilisation pour le traitement antimicrobien de surfaces
WO2004018435A1 (fr) * 2002-08-24 2004-03-04 Astrazeneca Ab Derives de la pyrimidine utilises comme modulateurs d'activite du recepteur de chimiokine
WO2004063192A1 (fr) * 2003-01-10 2004-07-29 Pharmacopeia Drug Discovery, Inc. Derives de d'imidazolyl pyrimidine utilises comme modulateurs du recepteur de il-8
WO2004069829A1 (fr) * 2003-01-10 2004-08-19 Pharmacopeia Drug Discovery, Inc. Derives d'aminoethylamide d'acide (2s)-2-((pyrimidin-4-yl)amino)-4-methylpentanoique utilises comme modulateurs du recepteur de l'il-8 pour traiter l'atherosclerose et la polyarthrite rhumatoide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517188A (en) 1983-05-09 1985-05-14 Mead Johnson & Company 1-Pyrimidinyloxy-3-hetaryl-alkylamino-2-propanols
JPS6339875A (ja) 1986-08-05 1988-02-20 Nissin Food Prod Co Ltd ピリミジン誘導体
JPH041192A (ja) 1990-04-17 1992-01-06 Nissan Chem Ind Ltd ピリジルピリミジン誘導体および農園芸用殺菌剤
DE69408750T2 (de) 1993-08-26 1998-07-23 Ono Pharmaceutical Co 4-Aminopyrimidin Derivate
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
DE19600934A1 (de) 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
SE508593C2 (sv) * 1996-03-29 1998-10-19 Stora Kopparbergs Bergslags Ab Limningskomposition samt förfarande för användning därav vid framställning av papper
JP2002241369A (ja) 1998-05-18 2002-08-28 Dainippon Pharmaceut Co Ltd ４−ピリミジニルアミノアセトアミド誘導体及びそれを含有する医薬組成物
BR0206968A (pt) * 2001-02-02 2004-03-09 Schering Corp Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como antagonistas receptores de quimiocina cxc
CA2451128A1 (fr) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company Inhibiteurs n-heterocycliques d'expression tnf-alpha

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0826673A1 (fr) * 1995-04-13 1998-03-04 Dainippon Pharmaceutical Co., Ltd. Derives de l'acetamide, procede de fabrication et composition medicamenteuse a base de ces derives
JPH10130150A (ja) * 1996-09-05 1998-05-19 Dainippon Pharmaceut Co Ltd 酢酸アミド誘導体からなる医薬
WO1998037079A1 (fr) * 1997-02-19 1998-08-27 Berlex Laboratories, Inc. Derives n-heterocycliques utiles en tant qu'inhibiteurs de la no synthetase
EP1110951A1 (fr) * 1998-08-27 2001-06-27 Sumitomo Pharmaceuticals Company, Limited Derives de pyrimidine
WO2001005783A1 (fr) * 1999-07-15 2001-01-25 Pharmacopeia, Inc. Antagonistes du recepteur b1 de la bradykinine
WO2003002542A1 (fr) * 2000-12-22 2003-01-09 Bristol-Myers Squibb Company Inhibiteurs n-heterocycliques de l'expression de tnf-alpha
WO2003077656A1 (fr) * 2002-03-15 2003-09-25 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines et leur utilisation pour le traitement antimicrobien de surfaces
WO2004018435A1 (fr) * 2002-08-24 2004-03-04 Astrazeneca Ab Derives de la pyrimidine utilises comme modulateurs d'activite du recepteur de chimiokine
WO2004063192A1 (fr) * 2003-01-10 2004-07-29 Pharmacopeia Drug Discovery, Inc. Derives de d'imidazolyl pyrimidine utilises comme modulateurs du recepteur de il-8
WO2004069829A1 (fr) * 2003-01-10 2004-08-19 Pharmacopeia Drug Discovery, Inc. Derives d'aminoethylamide d'acide (2s)-2-((pyrimidin-4-yl)amino)-4-methylpentanoique utilises comme modulateurs du recepteur de l'il-8 pour traiter l'atherosclerose et la polyarthrite rhumatoide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
E. F. ELSLAGER ET AL.: "Synthesis and Antimalarial Effects of 1-(3,4-Dichlorophenyl)-3-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-2-pyrimidinyl]guanidine and Related Substances", J. MED. CHEM., vol. 17, no. 1, 1974, pages 75 - 100, XP002297230 *
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 10 31 August 1998 (1998-08-31) *

Also Published As

Publication number Publication date
US20040087601A1 (en) 2004-05-06
US7037916B2 (en) 2006-05-02
WO2004062609A2 (fr) 2004-07-29

Similar Documents

Publication Publication Date Title
AU2003248978A1 (en) Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis
WO2003004480A3 (fr) Piperazines et diazepanes substitues
CA2523261A1 (fr) Derives de pyrimidine fusionnees a activite crf
PE20090835A1 (es) Derivados de quinazolina como inhibidores de la pi3 quinasa
MY140872A (en) 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibitory activity, compositions containing such derivatives and the use of such derivatives in the treatment of hypertension and other disorders
WO2005049581A8 (fr) Derives de pyridazine-3(2h)-ones et utilisation en tant qu'inhibiteurs de pde4
WO2005018557A3 (fr) Pyridinones substitues
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
ZA200609634B (en) Quinazolinone derivatives useful as vanilloid antagonists
WO2004094388A3 (fr) Methodes de traitement d'une maladie inflammatoire ou d'inhibition de la proteine jnk
PE20061078A1 (es) Derivados de piridotienopirimidina como inhibidores de la fosfodiesterasa 4 (pde4)
NO20055510L (no) 2-alkynyl- og 2-alkenylpyrazolo [4,3-E]-1,2,4-triazolo-[1,5-C]-pyrimidin-adenosin A2A-reseptorantagonister
NO20060702L (no) Aminokinolinderivater og deres anvendelse som adenosin A3 ligander
WO2004062609A3 (fr) Derives de pyrimidine utilises comme antagonistes des recepteurs de l'il-8
NO20080563L (no) Pyrazol[3,4-d]azepinderivater som histamin H3 antagonister
AU2003269364A1 (en) Use of piperazine derivatives as ccr1 antagonists
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
TW200730527A (en) Fused heterocyclic compound
WO2006134486A3 (fr) Composes alpha-(aryl-ou heteroaryl-methyl)-beta piperidino propanamide utiles en tant qu'antagonistes du recepteur orl1
WO2003068776A1 (fr) Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine
ATE429421T1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten
MXPA04003278A (es) Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina.
DE602004005016D1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
IS2424B (is) Þíenó[2,3-d]pýrimidín með sameinaðri LH og FSH gerandefnisvirkni
BRPI0313976B8 (pt) compostos de 7-fenilpirazolopiridina e uso dos mesmos na preparação de agente terapêutico ou profilático para doenças associadas com o crf ou seus receptores

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase